Cingulate Therapeutics
About Cingulate Therapeutics
Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).YEAR FOUNDED:
Dec. 1, 2012
LEADERSHIP:
Founder and CEO: Shane J. Schaffer
Founder and CSO: Raul R. Silva
Founder and CFO: Craig S. Tashjy
55 articles about Cingulate Therapeutics
-
Cingulate to Attend DCAT Week 2024 in New York City
3/6/2024
Cingulate Inc. announced that it will be attending DCAT Week March 18-21, 2024, in Midtown Manhattan.
-
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
2/13/2024
Cingulate Inc. announced that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin.
-
Cingulate Announces Closing of $7.5 Million Public Offering
2/6/2024
Cingulate Inc. announced the closing of its public offering of an aggregate of 3,750,000 shares of its common stock, Series A warrants to purchase up to 3,750,000 shares of common stock and Series B warrants to purchase up to 1,875,000 shares of common stock, at a public offering price of $2.00 per share and accompanying warrants.
-
Cingulate Announces Pricing of $7.5 Million Public Offering
2/2/2024
Cingulate Inc. announced the pricing of its public offering of an aggregate of 3,750,000 shares of its common stock, Series A warrants to purchase up to 3,750,000 shares of common stock and Series B warrants to purchase up to 1,875,000 shares of common stock, at a public offering price of $2.00 per share and accompanying warrants.
-
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
1/29/2024
Cingulate Inc. announced that Werth Family Investment Associates, LLC, the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $3.3 million of debt and accrued interest into Cingulate equity at a conversion price of $4.785 per share.
-
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
11/13/2023
Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company) today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update.
-
Cingulate to Host CNS Key Opinion Leader Panel in New York CityExpert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations
10/17/2023
Cingulate Inc. announced that it will be hosting a key opinion leader event on the morning of October 23, 2023, at the Union League Club in New York City.
-
Cingulate Inc. to Present at the LD Micro Main Event XVI
9/21/2023
Cingulate Inc. announced that Chairman & CEO, Shane J. Schaffer, will be presenting a company overview at the 16th annual Main Event on Wednesday, October 4th at 02:30 PM PT at the Luxe Sunset Boulevard Hotel.
-
Cingulate Announces Closing of $4.0 Million Public Offering
9/13/2023
Cingulate Inc. announced the closing of its previously announced public offering of an aggregate of 6,925,208 shares of its common stock, Series A warrants to purchase up to 6,925,208 shares of common stock and Series B warrants to purchase up to 3,462,604 shares of common stock, at a public offering price of $0.5776 per share and accompanying warrants.
-
Cingulate Announces Pricing of $4.0 Million Public Offering
9/11/2023
Cingulate Inc. announced the pricing of its public offering of an aggregate of 6,925,208 shares of its common stock, Series A warrants to purchase up to 6,925,208 shares of common stock and Series B warrants to purchase up to 3,462,604 shares of common stock, at a public offering price of $0.5776 per share and accompanying warrants.
-
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
9/11/2023
Cingulate Inc. announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301, for the treatment of attention deficit/hyperactivity disorder, presented on September 8th at the 36th Annual Psych Congress, in Nashville, TN.
-
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
9/8/2023
Cingulate Inc. announced that Werth Family Investment Associates, LLC, the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $5.8 million of debt and accrued interest into Cingulate equity, at a conversion price of $0.85 per share.
-
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023Data Accepted as Finalist for First Annual Poster Awards
9/5/2023
Cingulate Inc. announced the presentation of full results from the Phase 3 adult efficacy and safety trial of its lead candidate, CTx-1301, for the treatment of attention deficit/hyperactivity disorder at the 36th Annual Psych Congress, taking place September 6-10, 2023 in Nashville, TN.
-
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
8/14/2023
Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, provided financial results for the quarter ended June 30, 2023, as well as a clinical and business update.
-
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDResults Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration
7/11/2023
Cingulate Inc. announced positive top-line results from its Phase 3 adult trial of its lead candidate, CTx-1301, a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder, upon approval from the U.S. Food and Drug Administration.
-
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
6/14/2023
Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that Chairman and CEO Shane J. Schaffer, Pharm D, has been invited to participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.
-
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
6/8/2023
Cingulate Inc. today announced it has completed its Phase 3 adult dose-optimization trial of its lead candidate, CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).
-
Cingulate to Present at 13th Annual LD Micro Invitational
5/25/2023
Cingulate Inc. announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023.
-
Cingulate, Indegene to Participate in Benzinga All Live Access Event
5/12/2023
Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.
-
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
5/10/2023
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update.